- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01324115
NG-Nitro-L-Arginine in Treating Patients With Advanced Solid Tumors
A Phase I Trial of NG-Nitro-L-Arginine (L-NNA), a Nitric Oxide Synthase Inhibitor, Given as a Single Intravenous Infusion Over 10 Minutes in Patients With Advanced Solid Tumors
RATIONALE: NG-nitro-L-arginine may stop the growth of tumor cells by disrupting blood flow to the tumor.
PURPOSE: This phase I trial is studying the side effects and best dose of NG-nitro-L-arginine in treating patients with advanced solid tumors.
Study Overview
Status
Detailed Description
OBJECTIVES:
Primary
- To determine if there is a differential effect of NG-nitro-L-arginine (L-NNA) on tumor and normal tissue vasculature (blood flow/volume) in patients with advanced solid tumors in order to propose a safe recommended dose range for further evaluation.
Secondary
- To determine the correlation between plasma concentration of L-NNA and toxicity and vascular effects.
- To further determine the effects of nitric oxide synthase (NOS) inhibition on tumor tissue vasculature.
- To determine the pharmacokinetics of L-NNA.
- To determine the safety profile of L-NNA.
Tertiary
- To evaluate the potential pharmacodynamic effect of NOS inhibition on angiogenesis.
- To evaluate the effect of L-NNA on circulating NOS levels.
- To evaluate the correlation between expression levels of iNOS and eNOS and vasoconstrictive effects of L-NNA in tumor tissue (where available).
OUTLINE: This is a dose-escalation study.
Patients receive a single dose of NG-nitro-L-arginine (L-NNA) IV over 10 minutes on day 1. All patients undergo up to 6 dynamic contrast-enhanced computed tomography (DCE-CT).
Patients enrolled in the expanded cohort study undergo 4 additional scans of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) as well as DCE-CT scans.
Blood samples are collected periodically for pharmacokinetic and biomarker studies. Samples are analyzed for L-NNA levels via a reverse-phase high performance liquid chromatography, NOS inhibition via cGMP analysis, and VEGF-A and osteopontin levels. Previously collected biopsy samples are analyzed for iNOS and eNOS expression.
After completion of study treatment and one week assessments, patients are followed up once a week for 28 days and then monthly thereafter (if required).
Peer Reviewed and Funded or Endorsed by Cancer Research UK.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
England
-
Northwood, England, United Kingdom, HA6 2RN
- Mount Vernon Cancer Centre at Mount Vernon Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed advanced solid tumor
- Refractory to conventional treatment or for which no conventional therapy exists or therapy is declined by the patient
Disease assessable by DCE-CT
- Must be a minimum size of 2 cm measured on the longest axis
Disease assessable by DCE-MRI (patients enrolled in the expanded cohort study only)
- Must be in sites that do not move with respiration or vascular pulsation unless this can be compensated for
- No squamous cell carcinomas
PATIENT CHARACTERISTICS:
- WHO performance status 0-1
- Life expectancy ≥ 12 weeks
- Hemoglobin ≥ 10.0 g/dL
- Absolute neutrophil count ≥ 1.5 x 10^9/L
- Platelet count ≥ 100 x 10^9/L
- Serum bilirubin ≤ 1.5 times upper limit of normal (ULN)
- ALT/AST ≤ 2.5 times ULN (≤ 5 times ULN if due to tumor)
- Glomerular filtration rate ≥ 50 mL/min (uncorrected) assessed by ^51Cr-EDTA
- INR ≤ 1.4 sec
- Serum potassium normal
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use 2 forms of highly effective contraception (1 for men) 4 weeks prior to, during, and for 6 months after completion of study therapy
- No post-radiation bowel symptoms of any grade following radiotherapy within the abdomen or pelvis
- No high medical risk due to non-malignant systemic disease, including active uncontrolled infection
- No known serologically positive hepatitis B or C or HIV
- No previous or suspected allergy to imaging contrast medium
No heart disease, including any of the following:
- History of angina (including Prinzmetal angina) or myocardial infarction (including pathological Q waves on 12-lead ECG )
- History of heart failure
- History of hemodynamically significant arrhythmia (not including atrial fibrillation with well-controlled ventricular rate)
- Cardiomyopathy (including hypertrophic cardiomyopathy, dilated cardiomyopathy, or arrhythmogenic right ventricular cardiomyopathy)
- Hemodynamically significant valvular abnormalities (including aortic valve stenosis)
- Congenital heart disease
- LVEF ≥ 50% by ECHO or MUGA scan
- No QT prolongation (QTc ≥ 470 msec for women and ≥ 450 for men) or any other clinically significant ECG abnormality
- No peripheral arterial disease (including all diseases caused by obstruction of large arteries in arms and legs, abdominal aortic aneurism, previous aortic dissection, or connective tissue disease resulting in thoracic aortic dilation, such as Marfan syndrome)
- No current hypertension, defined as BP consistently greater than 140/90 mm Hg or the requirement for anti-hypertensive drug treatment
- No history of thromboembolic disease or platelet/clotting disorders
- No history of cerebrovascular disease (e.g., transient ischemic attack or stroke)
- No clinically significant history of renal or hepatic impairment
- No diabetes mellitus
- Able to tolerate and comply with imaging protocol (patients with high levels of pain, urinary incontinence, or claustrophobia should be excluded)
- No other condition which, in the investigator's opinion, would not make the patient a good candidate for the clinical trial
- No pacemakers or implantable cardioverter defibrillators (for patients enrolled in the expanded cohort study only)
- No metal fragments in the eyes, shrapnel, or bullet injuries (for patients enrolled in the expanded cohort study only)
PRIOR CONCURRENT THERAPY:
- Recovered from all previous toxicities (except for alopecia or certain Grade 1 toxicities that, in the opinion of the investigator and the Drug Development Office, should not exclude the patient)
At least 6 weeks since prior endocrine therapy
- Stable therapy allowed if there has been no changes to the therapy within six weeks prior to treatment with L-NNA
- At least 6 weeks since prior major surgery (for patients enrolled in the expanded cohort study only)
- At least 4 weeks since prior radiotherapy (except for control of bone pain outside of the investigation site for CT evaluation), immunotherapy, or chemotherapy (6 weeks for nitrosoureas and mitomycin C)
- No prior heart or brain surgery (for patients enrolled in the expanded cohort study only)
- No major thoracic or abdominal surgery from which the patient has not yet recovered
- No concurrent drugs known to affect vascular tone (e.g., angiotensin-converting enzyme inhibitors or nitrates)
- No concurrent anticoagulants (1 mg warfarin for central line maintenance is acceptable during the trial) or anti-hypertensives
- At least 72 hours since prior non-steroidal anti-inflammatory drugs (NSAIDs), including cyclooxygenase 2 (COX2) inhibitors
No concurrent participation or plan to participate in another interventional clinical trial
- Participation in an observational trial is acceptable
- At least 14 days since prior and no concurrent medicines known to prolong QTc, including domperidone
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Dose-limiting toxicities (DLT) and/or subsequent maximum dose
|
Dose at which there is no additional differential effect of L-NNA on the tumor vasculature as measured by dynamic contrast-enhanced computed tomography (DCE-CT)
|
Pharmacokinetic (predominantly AUC-dependent specific vascular effects) dependent effects (duration and magnitude of effect on blood flow/volume) in the tumor tissue compared to renal tissue using data from volumetric assessments via DCE-CT
|
Secondary Outcome Measures
Outcome Measure |
---|
Effect on tumor blood perfusion using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) with additional blood oxygen level-dependent (BOLD) imaging and diffusion-weighted imaging (DWI) sequences
|
Causality of each adverse event to L-NNA and severity grade according to NCI CTCAE Version 4.02
|
Tertiary Outcome(s) - Measurement of L-NNA concentrations in plasma samples
|
Measurement of serum biomarker concentrations, osteopontin, and vascular endothelial growth factor (VEGF-A)
|
Measurement of NOS concentrations in circulating blood (cyclic guanine monophosphate analysis)
|
Measurement of iNOS and eNOS expression levels in pre-treatment tumor biopsy samples (where available)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CDR0000697500
- CRUK-CR0709-11
- EUDRACT-2009-013621-42
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Unspecified Adult Solid Tumor, Protocol Specific
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingCollection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid TumorsUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Kantonsspital GraubuendenUnknownUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificSwitzerland
-
National Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Vanderbilt UniversityNational Cancer Institute (NCI)TerminatedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
University of ChicagoNational Cancer Institute (NCI)CompletedSirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By SurgeryUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)WithdrawnUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol Specific
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyWithdrawnUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol Specific | Hematopoietic/Lymphoid CancerUnited States
-
University of Texas Southwestern Medical CenterRecruitingUnspecified Adult Solid Tumor, Protocol SpecificUnited States
Clinical Trials on pharmacological study
-
National Cancer Institute (NCI)TerminatedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
National Cancer Institute (NCI)CompletedExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditionsUnited States
-
Universitätsmedizin MannheimHeidelberg UniversityUnknownLung Cancer | Brain and Central Nervous System TumorsGermany
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI); Peloton Therapeutics, Inc.CompletedRecurrent GlioblastomaUnited States
-
National Cancer Institute (NCI)TerminatedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
National Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Recurrent Childhood Soft Tissue Sarcoma | Recurrent Childhood Brain Stem Glioma | Recurrent Childhood Visual Pathway Glioma | Childhood Central Nervous System Germ Cell Tumor | Childhood Central Nervous System Choriocarcinoma | Childhood Central... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Cutaneous T-cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides/Sezary SyndromeUnited States
-
National Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol Specific | Male Breast Cancer | Stage IV Breast Cancer | Stage IV Ovarian Epithelial Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer | Recurrent Breast Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Stage...United States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedMyeloid Proliferations Associated With Down SyndromeUnited States, Canada, Australia, Puerto Rico